Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AeriSeal BLVR System in Advanced Emphysema
NCT00205920Phase 2Terminated
- Sponsor
- Aeris Therapeutics
- Start
- May 2005
- Primary completion
- Sep 2006
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AeriSeal in pulmonary emphysema, sponsored by Aeris Therapeutics. Primary endpoints: Product-related life-threatening adverse events, permanently disabling complications and deaths at 1 year, Forced Expiratory Volume in 1 second at 12 weeks and 3 more. Started May 2005; status: terminated.
02
Drugs
AeriSeal
03
Conditions
pulmonary emphysema
Beyond the preview
Go deeper on NCT00205920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00205920.